Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger and BTB domain-containing protein 20 (ZBTB20) is a transcription factor characterized by an N-terminal BTB/POZ domain and multiple C2H2-type zinc finger motifs at the C-terminus[1][3][5]. ZBTB20 acts mainly as a transcriptional repressor, regulating diverse biological processes such as cellular development and differentiation, metabolism, and innate and adaptive immune responses[1][2][6]. It is important in hematopoietic tissues and is highly homologous to BCL6, another key BTB/POZ family member[1]. ZBTB20 has garnered attention for its roles in tumorigenesis, being a hotspot for genetic variation and fusion in various cancers[1]. Pathogenic mutations in ZBTB20 are associated with Primrose syndrome and other developmental conditions[4]. No approved small-molecule drugs or biologics currently target ZBTB20 directly; however, its functional domains are considered promising therapeutic candidates in oncology and immune modulation[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger and BTB domain-containing protein 20 (ZBTB20).